Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection. However, the prophylactic benefits of HCQ has not been clearly defined yet.
This study is designed to evaluate the prophylactic efficacy of HCQ in COVID-19 cases with mild to moderate symptoms and in the hospital staff engaged in attending infected patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Patients will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course. Staff will receive HCQ sulfate 400mg/week for 4 weeks
Time to reach normal body temperature
Time to reach normal body temperature (TNBT), ≤37.50 C
Time frame: 1 month
Development of COVID-19 symptoms during HCQ preventive therapy in staff
Development of fever and/or other symptoms of COVID-19 during the 1 month of the HCQ therapy
Time frame: 1 month
COVID-19 test result at follow-up in patients
Viral RNA test results at day 6 will be compared between the HCQ vs no-HCQ group
Time frame: 6 days
Worsening of symptoms in COVID-19 patients
Worsening of symptoms in COVID-19 patients requiring artificial ventilation during the study period
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.